It is plausible that our use of the novel PEA technology, which is more sensitive compared to standard enzyme linked immunosorbent assay (ELISA) (32, 33), combined with our sizeable and controlled cohort allowed us to demonstrate a previously unappreciated difference in IL-18 levels in NASH-patients. The gene discussed is IL18; the disease is metabolic dysfunction-associated steatohepatitis.